Rubicon Research Ltd (RUBICON) is currently trading at 1,609.90 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.

Rubicon Research Limited is an integrated Indian pharmaceutical company focused on research, development and manufacturing of specialty formulations and drug‑device combinations for regulated markets, particularly the United States, operating multiple manufacturing sites in India and owning US marketing and logistics subsidiaries following recent acquisitions. Q1 FY27 was materially strong: consolidated revenue rose 52% year‑on‑year to INR5,343 million with USD revenues at USD55 million (+32% Y/Y), gross margin improved to 67.7% and operating EBITDA expanded to 24.2%, while PAT nearly doubled to INR848 million aided by a one‑off insurance claim in other income. The company is executing a deliberate M&A and capacity strategy: closed the Arinna Lifesciences (85%) acquisition in April 2026, acquired a US manufacturing site in East Brunswick for USD2.9 million, and continues to ramp Pithampur (acquired from Alkem) with commercialization targeted in calendar year 2027. R&D remains a core competitive lever: consolidated R&D spend was 10.9% of revenue in Q1 with a guided INR500 crore deployment across FY26–27 and Q1 FY28, and management reports a current R&D productivity metric of ~5.5x on a rolling basis, indicating strong incremental revenue per R&D rupee. Management highlighted quality and compliance as strategic priorities and has reallocated management bandwidth—CFO transitioning to Chief Commercial Officer while a new CFO designate joins—underscoring a focus on commercialization, scale‑up and long‑term organizational readiness.

Over the past 52 weeks, Rubicon Research Ltd has traded between a low of ₹607.30 and a high of ₹1,896.15. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.

Rubicon Research Ltd has a market capitalization of approximately 25,834.86. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.

Rubicon Research Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 89.64 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.

Based on its market capitalization of 25,834.86 Cr, Rubicon Research Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.

Rubicon Research Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.

The Price-to-Earnings (PE) ratio of Rubicon Research Ltd is 89.64. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.

The disclosure in the provided text states General Atlantic Singapore RR Pte. Ltd. disposed of 1,40,00,000 equity shares over Aug 25-26, 2026.

The text cites an 8.45% stake sale over Aug 25-26, 2026, and also describes the Aug 26 block deals as roughly 8.4% (about 8.37% to 8.38%).

Consolidated revenue from operations was ₹534.34 crore (+51.6% YoY) and PAT was ₹84.78 crore (+95.8% YoY) for Q1FY27.

For the quarter ended June 2026, sales were ₹534.34 crore and net profit was ₹84.78 crore, as per the figures provided.